Ask AI

Team Strategies for Overcoming Challenges to Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer

Enhance your ability to optimally integrate CDK4/6 inhibitors into practice for HR-positive/HER2-negative early breast cancer based on key clinical evidence and expert recommendations through a certified on-demand webcast and interactive case challenges as well as a ClinicalThought commentary and downloadable slides.

Share

Program Content

Activities

Early Breast Cancer Management Forum
ClinicalThought Expert Office Hours Forum: Navigating Treatment Decisions in High-Risk HR+/HER2- Early Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 20, 2026

Provided by

ProCE Banner

Provided by National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner